What Remedy Meds gets right, and what the FDA letter changes
Remedy Meds sells compounded GLP-1 weight loss treatment on a flat monthly subscription: an online health questionnaire, a prescribing clinician, medication shipped to your door, and a member portal to run the account. Two drug substances carry the whole service, semaglutide and tirzepatide, both prepared by a compounding pharmacy rather than a brand manufacturer, which means neither is an FDA-approved product and neither has been reviewed for bioequivalence against Wegovy, Ozempic, Mounjaro or Zepbound. The company holds LegitScript certification, a third-party check on licensure and prescribing practice that plenty of compounded sellers never bother to obtain. It also received an FDA warning letter dated September 9, 2025 about how its website described compounded tirzepatide. If you want a cash-pay route to incretin therapy with no insurance paperwork, this works; if you want brand-name medicine, an oral option, or a company with a clean regulatory file, keep shopping.
How the money works, and what to pin down before the first charge
Flat monthly billing instead of per-milligram pricing
Most people looking for a Remedy Meds review arrive with two questions: what the monthly charge really is, and how hard it is to stop paying it. The company advertises flat subscription billing that covers the medication, rather than charging by the milligram. That structure matters on an incretin drug, because doses usually climb over the first few months. Under per-milligram pricing, every step up costs more; under flat billing, the charge is meant to hold steady at maintenance strength.
Get that promise in writing before intake, and ask specifically whether the rate still applies at the highest dose you might reach. Prices in compounded GLP-1 telehealth move often, so treat any figure quoted on a third-party site as a starting point and confirm the current rate at the company’s own checkout. We desk-verify provider pricing against the live site and re-check it monthly; this page carries a dated verification block for that check.
What the subscription is meant to cover, and what bills separately
Ask for a line-by-line answer before you pay. The list worth running through is short: the medication itself, the clinician consult, dose adjustments, shipping, syringes and needles, and follow-up messaging. Cash-pay weight services differ on which of those sit inside the monthly fee and which arrive as an extra charge.
Bloodwork is the usual gap. Many compounded programs do not order baseline labs, which keeps the headline rate lower and shifts responsibility for kidney function, liver enzymes and HbA1c onto you and your regular doctor. That is not automatically wrong, but it is a real cost and a real safety task you inherit.
Do the annual arithmetic before you decide anything is affordable. A monthly rate that feels manageable in isolation looks different across twelve months, and weight regain after stopping is common, so many people are budgeting for longer than they first assume.
What a year actually costs
Programmes quote a monthly headline. Add the medication, the labs and the renewal price and the real number is usually different.
Advertised prices change often and intro pricing rarely lasts. Ask what the renewal rate is before you commit to a plan.
Cash pay only, and what that means for insurance
This is a self-pay service. Compounded drugs are generally excluded from Medicare Part D, which covers approved products, so a compounded semaglutide or tirzepatide prescription will not usually be reimbursed there; the Medicare drug coverage rules are worth reading if you are on a Part D plan (Medicare Part D drug coverage). Commercial insurers rarely pay for compounded copies either. The trade is simple: you skip prior authorisation and formulary fights, and you absorb the entire cost.
Cancelling, renewals and refunds
Subscription anxiety dominates public discussion of this company, and it is the part to handle before you hand over a card. Ask three questions and keep the answers: how much notice cancellation requires, whether an unshipped order can be refunded once billed, and whether month two bills at the same rate as month one.
Then make the mechanics boring. Cancel through the member portal rather than by phone alone, screenshot the confirmation, note your billing date in a calendar, and email support so a written record exists. If a charge lands after cancellation, that paper trail is what a card issuer will ask for.
Compounded semaglutide: what the track involves
How the medicine works
Semaglutide is a GLP-1 receptor agonist, a medicine that copies a gut hormone controlling appetite and blood sugar. It slows stomach emptying, reduces hunger signalling in the brain and improves insulin response after meals. In the pivotal trial of the approved brand product, adults with obesity and no diabetes lost roughly fifteen percent of body weight over 68 weeks alongside diet and activity changes (peer-reviewed trial report).
That evidence belongs to the approved product. Compounded semaglutide has not been through the same review, and no regulator has confirmed that a compounded vial delivers the same amount of drug as a brand pen. Treat trial numbers as context for the molecule, not a guarantee from this pharmacy. Our compounded versus brand semaglutide explainer covers the difference in more depth.
Compounded Semaglutide vs. Tirzepatide at Remedy Meds
| Compounded Semaglutide | Compounded Tirzepatide | |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GIP + GLP-1 receptor agonist |
| Trial weight loss (brand product) | ~15% over 68 weeks | ~20% over 72 weeks |
| FDA warning letter | None on record | Yes - marketing claims, Sept 9 2025 |
| Shortage resolution | Feb 2025 | Dec 2024 |
| Best fit | First-time GLP-1 users, cautious starters | Plateaued on GLP-1 alone, higher-result seekers |
Titration and what a dose schedule looks like
Approved semaglutide labelling uses a stepwise climb: a low starting dose held for several weeks, then planned increases toward a maintenance dose, mainly to limit nausea. Compounded services usually mirror that shape, but the delivery differs. Brand pens click through set doses; compounded vials require drawing a measured volume into a syringe, and unit-based instructions have caused real dosing errors, which the FDA has flagged directly (FDA safety information on unapproved GLP-1 drugs).
Ask who signs off each increase, how quickly a clinician answers if you need to hold a dose, and whether the schedule is written down in the portal or improvised over messages. A titration plan you can see is worth more than one you have to reconstruct from emails.
Side effects worth planning for
- Nausea, vomiting, diarrhoea, constipation and abdominal pain, most common while the dose is rising
- Dehydration from persistent vomiting or diarrhoea, which can strain the kidneys
- Gallbladder problems, including stones, particularly with rapid weight loss
- Pancreatitis, signalled by severe abdominal pain that spreads to the back
- Low blood sugar when combined with insulin or a sulfonylurea
Who this track suits
Semaglutide suits someone who wants the better-established molecule of the two, has tolerated GLP-1 therapy before, or is starting cautiously. It also suits people who plan to move to a brand product later and want a familiar side-effect profile first.
Compounded tirzepatide, and the claim that drew the FDA letter
A different mechanism
Tirzepatide acts on two receptors, GIP and GLP-1, rather than one. In the main trial of the approved brand product, adults with obesity lost around twenty percent of body weight at the highest dose over 72 weeks (SURMOUNT-1 trial report). Those results have made tirzepatide the requested molecule at most cash-pay clinics, including this one.
The same caution applies twice over here. Trial data describes Zepbound and Mounjaro, not a compounded preparation, and the gap between the two is exactly what the FDA raised with this company. Dosing, storage and injection technique are covered in our tirzepatide side effects and dosing explainer.
What the FDA objected to
The warning letter, MARCS-CMS 716830, dated September 9, 2025, addressed website statements presenting compounded tirzepatide as containing the same active ingredient as the approved brand products. The agency’s position is that such wording implies an approval compounded medicines do not hold, and the letter was issued under the heading of unlawful sale of unapproved and misbranded drugs over the internet (FDA warning letter).
Read that for what it is. A warning letter is a formal notice demanding corrective action; it is not a recall, a seizure, or an order to close. It also does not tell you that any particular vial was contaminated or underdosed. What it does tell you is that the agency examined this company’s marketing and found it misleading, which is a fair thing to weigh when the same marketing is what convinced you the product equals the brand.
Side effects and tolerability
Gastrointestinal effects dominate here too, and can be more pronounced at higher doses: nausea, vomiting, diarrhoea, constipation, reflux and fatigue. The serious warnings track the class, including pancreatitis, gallbladder disease and thyroid C-cell tumour findings in rodents. Prescribing information for both molecules is available through DailyMed prescribing information.
Who this track suits
Tirzepatide tends to suit people who have already plateaued on a GLP-1 alone, or who want the stronger average result and accept a higher chance of gut side effects while titrating. It is a poor fit for anyone who cannot tolerate a slow dose climb or who has a history that rules out the class.
How the two tracks compare inside this service
| Attribute | Compounded semaglutide | Compounded tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| Regulatory status of the preparation | Compounded, not FDA approved | Compounded, not FDA approved; subject of the 2025 warning letter |
| Trial evidence for the molecule | Approved brand product studied over 68 weeks | Approved brand product studied over 72 weeks |
| Typical dose pattern | Weekly injection, stepwise increases | Weekly injection, stepwise increases |
| Monitoring you should arrange | Baseline and periodic bloodwork with your own clinician | Baseline and periodic bloodwork with your own clinician |
| Question to ask the clinic | Which pharmacy compounds it, and is potency tested | Same, plus how dosing is expressed on the vial label |
What compounded actually means here
Compounded medicines are made by pharmacies for individual patients, under state or federal oversight, and they sit outside the FDA approval process by design. They are not tested for safety, effectiveness or manufacturing quality the way approved drugs are, which the agency spells out plainly in its compounding guidance (FDA compounding questions and answers).
The legal room for compounding these two molecules also narrowed once the FDA declared the national shortages resolved, tirzepatide in December 2024 and semaglutide in February 2025. Compounders can still prepare personalised formulations for specific clinical needs, but copies of commercially available drugs are a different matter. Ask which pathway your prescription sits in and expect a clear answer.
Four questions separate a careful compounded service from a careless one:
- Which pharmacy prepares the medication, in which state, and is it a 503A pharmacy or a 503B outsourcing facility
- Is every batch tested by an independent lab for potency and sterility, and can you see a certificate of analysis
- Is the formulation plain semaglutide or tirzepatide, or is it mixed with additives such as vitamin B12
- How is the dose written on the label, in milligrams or in syringe units, and who checks that you understood it
Signing up: the steps from questionnaire to first shipment
Step 1: the intake questionnaire
You complete an online health history covering height, weight, current medications, past weight loss attempts and relevant conditions. Answer thyroid, pancreatitis and pregnancy questions precisely; these are the items that should stop a prescription, and rushing them is how people end up on a medicine that was never right for them.
Step 2: check where you sit on the standard criteria
Obesity-medicine prescribing usually starts at a BMI of 30, or 27 with a weight-related condition such as high blood pressure, sleep apnoea or type 2 diabetes. Work out your number before intake so you know whether you are inside the usual range.
BMI calculator
Most weight-loss programmes screen on BMI before they will prescribe. This is the number they will use.
A screening number, not a diagnosis. It does not distinguish muscle from fat, and it reads high for muscular builds.
Step 3: clinician review
A licensed prescriber reviews the intake. Confirm whether that happens asynchronously from your written answers or through a live video visit, and ask whether you can request a call if something in your history needs discussion. Asynchronous review is faster; it also means nobody hears the hesitation in your voice.
Step 4: payment, pharmacy and shipping
Payment triggers the pharmacy order. Ask how the medication ships, whether it travels with cold packs, what to do if a parcel arrives warm or delayed, and how quickly a replacement is sent. Refrigeration failures are the most common practical problem in mail-order injectables.
Step 5: first injection and follow-up
From Questionnaire to First Injection
- Complete online health history - answer thyroid, pancreatitis and pregnancy questions precisely
- Confirm your BMI meets criteria (30+, or 27+ with a weight-related condition)
- Clinician reviews intake - confirm async or live video, and whether a call is available
- Pay to trigger pharmacy order - ask about cold-pack shipping and replacement policy
- Receive medication - verify written injection instructions, disposal guidance, and follow-up schedule before first dose
Before the first dose, you should have written instructions, injection sites, sharps disposal guidance and a named route to ask questions. Confirm when the first follow-up is scheduled and whether dose increases require a new consult.
Where the service operates
Telehealth prescribing depends on the state you are physically in when you complete intake, and coverage maps change. Check your state at the start of the questionnaire rather than after payment, and if you split time between two states, use the one where you will actually receive shipments.
Prescribers, refills and the portability problem
Care runs through the member portal: messaging, refill requests, account settings and billing. That is a genuine convenience compared with phone-only services, and it is where cancellation should also live.
One structural limitation deserves attention. No Surescripts e-prescribing footprint appears on record for this company, which suggests prescriptions are routed to its partner compounding pharmacy rather than transmitted to a retail pharmacy of your choice. Practically, that means your prescription is not portable. If you cancel, or if a shipment stalls, you cannot simply pick it up at a local counter. You start again with a new clinician.
Ask two things about refills: how many days before you run out the next shipment is dispatched, and what happens if a dose change is pending. Gaps matter on incretin therapy, because a long break can mean restarting titration and repeating the worst of the nausea.
Support: response times and getting a person
Support runs through the portal and customer service contact routes. Public search behaviour around this brand skews heavily toward login, portal, phone number and cancellation queries, which is a reasonable proxy for where friction sits: people can start easily, then look for a human later.
Before you sign up, send a test question through the contact form and see how long a reply takes. It costs nothing and tells you more than any marketing page. Also establish what counts as an escalation: who reviews a side effect report, how fast, and whether after-hours contact exists at all. For anything urgent, a telehealth service is not the right channel, and knowing that in advance prevents a dangerous wait.
Privacy and data practices to check before intake
Clinical records held by a telehealth provider generally fall under HIPAA, but the consumer layer around them often does not. Marketing pixels, advertising identifiers and app analytics can sit outside the clinical record entirely, and weight loss data is unusually sensitive.
Read the notice of privacy practices and the separate privacy policy, then look for four specifics: what data is collected beyond your medical answers, whether any of it is shared with advertising partners, how to request deletion of your account and records, and how payment card details are stored. If the policy is vague on advertising sharing, ask in writing and keep the answer. A company that responds clearly on data usually responds clearly on billing too.
The trust and safety record, stated plainly
Two verifiable records define this provider, and they point in opposite directions.
On the positive side, the company holds LegitScript certification. That programme reviews licensure, prescribing practice and business legitimacy for telehealth and pharmacy operations, and status can be confirmed independently through the LegitScript certification lookup. Plenty of compounded GLP-1 sellers never seek it, so its presence is meaningful.
On the negative side sits the September 9, 2025 warning letter over marketing claims for compounded tirzepatide. The agency’s concern was the impression of approval, and that concern is exactly the one a patient should hold: compounded incretins are not approved products, however closely their ingredient names track the brands. The company remained in business after the letter, its site and member portal stayed live, and no recall or closure appears on the public record.
Pricing transparency lands in the middle. Flat monthly billing is easier to understand than per-milligram tiers, but cancellation notice periods and refund terms are the parts patients most often say they discovered late. Get both in writing first. Our provider scoring methodology explains how a regulatory action like this constrains a trust score regardless of other strengths.
Safety essentials for GLP-1 therapy
These medicines are effective and they are not casual. Approved labelling for both molecules carries a boxed warning based on thyroid C-cell tumours in rodents, and they should not be used by anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. They are not for type 1 diabetes, and they are not for use in pregnancy or while trying to conceive.
Tell any prescriber about a history of pancreatitis, gallbladder disease, severe gastrointestinal disease including gastroparesis, diabetic retinopathy, or kidney impairment. Flag insulin or sulfonylurea use, because doses of those often need reducing to avoid hypoglycaemia. Mention upcoming surgery or any procedure with sedation, since delayed stomach emptying raises aspiration risk under anaesthesia.
Contact a clinician promptly for severe abdominal pain radiating to the back, persistent vomiting or an inability to keep fluids down, right upper abdominal pain with fever or yellowing skin, a neck lump or hoarseness that does not settle, or signs of low blood sugar. Sensible monitoring during treatment includes weight, blood pressure, kidney function and, for people with diabetes, HbA1c. General background on medical weight management is available from NIDDK guidance on obesity medications.
Who this provider suits, and who should look elsewhere
The service makes sense for a self-pay patient who wants both incretin molecules available from one clinic, prefers predictable flat billing while doses climb, has no insurance route to a brand product, and is comfortable with a compounded preparation after reading the regulatory record honestly.
Look elsewhere if any of the following apply. You have coverage that could pay for Wegovy or Zepbound, in which case a service that handles prior authorisation is worth more than a low cash rate. You want an oral option or a non-incretin alternative. You want baseline labs ordered and reviewed inside the program. You want a prescription you can move to a local pharmacy. Or a regulatory action against a company’s marketing is, by itself, a dealbreaker for you, which is a defensible position rather than an overreaction.
If you are still weighing routes, the live rankings and price checks on our GLP-1 telehealth comparison show how cash-pay compounded services stack against brand-access programs, and the telehealth provider directory covers the wider field.
Questions to ask before your first charge
Bring these to the clinic, in writing, and keep the replies:
Questions to Get in Writing Before Your First Charge
- Does the monthly rate hold at the highest maintenance dose and at renewal?
- What is the cancellation notice period, and can an unshipped order be refunded?
- Which pharmacy compounds the medication, and is batch potency testing documented?
- Is the dose label written in milligrams or syringe units?
- Are baseline labs required, or do you arrange them with your own doctor?
- Who is your prescriber and how do you reach a clinician about a side effect?
- Does the prescription route to a partner pharmacy only, or can you use a local pharmacy?
- Does the monthly rate change at higher maintenance doses, and does it change at renewal
- What is the cancellation notice period, and can an unshipped order be refunded
- Which pharmacy compounds the medication, and is batch testing documented
- Who is my prescriber, and how do I reach a clinician about a side effect
- Are labs required, and if not, what should I ask my own doctor to order
If you are switching from another service, ask your current provider three more: how to obtain your records, when your last shipment ships, and the exact date your billing stops. Overlapping subscriptions are the most common avoidable cost in this category. Work the total through our Run My Numbers calculators first, and the sample savings report shows the format we use for cash-pay comparisons.
Quick tip: screenshot the checkout page showing the rate and the billing terms before you confirm payment.
Reputation check
The public record on this company is unusually clear-cut, which makes it easier to judge than most. The FDA warning letter dated September 9, 2025 is the heaviest document, and it concerns marketing language rather than any finding about product quality. LegitScript certification pulls in the other direction and is independently checkable. Both are facts, and neither cancels the other.
Community sentiment, drawn from public discussion in Reddit’s compounded tirzepatide forum, clusters on two themes. The first is price: posters repeatedly describe the monthly rate as high relative to other compounded sellers, while conceding the pharmacies used appear legitimate. The second is cancellation, with several threads written by people worried about stopping charges cleanly after a first payment. Autocomplete and related-search behaviour reinforce the same picture, dominated by login, portal, phone number and cancellation queries rather than clinical questions.
A Trustpilot profile for the company also exists and collects customer service feedback, which is worth reading for delivery and support anecdotes, though ratings there shift and should be checked at the source rather than quoted second-hand. Treat all of that as sentiment about the buying experience, not as evidence about what is in the vial. Community reviews collected on this site are moderated, and sponsored placements, where they appear anywhere on the site, are labelled and never affect scores or rankings.
Educational content, not medical advice. Always consult a qualified clinician before starting, stopping or switching treatment.